Tags

Type your tag names separated by a space and hit enter

The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response.
J Immunother Cancer. 2020 05; 8(1)JI

Abstract

The pandemic caused by the novel coronavirus SARS-CoV-2 has placed an unprecedented burden on healthcare systems around the world. In patients who experience severe disease, acute respiratory distress is often accompanied by a pathological immune reaction, sometimes referred to as 'cytokine storm'. One hallmark feature of the profound inflammatory state seen in patients with COVID-19 who succumb to pneumonia and hypoxia is marked elevation of serum cytokines, especially interferon gamma, tumor necrosis factor alpha, interleukin 17 (IL-17), interleukin 8 (IL-8) and interleukin 6 (IL-6). Initial experience from the outbreaks in Italy, China and the USA has anecdotally demonstrated improved outcomes for critically ill patients with COVID-19 with the administration of cytokine-modulatory therapies, especially anti-IL-6 agents. Although ongoing trials are investigating anti-IL-6 therapies, access to these therapies is a concern, especially as the numbers of cases worldwide continue to climb. An immunology-informed approach may help identify alternative agents to modulate the pathological inflammation seen in patients with COVID-19. Drawing on extensive experience administering these and other immune-modulating therapies, the Society for Immunotherapy of Cancer offers this perspective on potential alternatives to anti-IL-6 that may also warrant consideration for management of the systemic inflammatory response and pulmonary compromise that can be seen in patients with severe COVID-19.

Authors+Show Affiliations

MacroGenics Inc, Rockville, Maryland, USA.John Wayne Cancer Institute and Cancer Clinic, Providence Saint John's Health Center, Santa Monica, California, United States. Providence Los Angeles Metro Hospitals, Santa Monica, California, United States.Herbert Irving Cancer Center, Columbia University Medical Center, New York, New York, USA.Earle A Chiles Research Institute, Portland, Oregon, USA.University of Science and Technology of China, Hefei, Anhui, China.Earle A Chiles Research Institute, Portland, Oregon, USA.A.O.R.N. dei Colli Monaldi-Cotugno-CTO Hospitals, Naples, Italy.Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA.University of Science and Technology of China, Hefei, Anhui, China.Frederick, Maryland, USA.Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Napels, Italy paolo.ascierto@gmail.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32385146

Citation

Arnaldez, Fernanda I., et al. "The Society for Immunotherapy of Cancer Perspective On Regulation of Interleukin-6 Signaling in COVID-19-related Systemic Inflammatory Response." Journal for Immunotherapy of Cancer, vol. 8, no. 1, 2020.
Arnaldez FI, O'Day SJ, Drake CG, et al. The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response. J Immunother Cancer. 2020;8(1).
Arnaldez, F. I., O'Day, S. J., Drake, C. G., Fox, B. A., Fu, B., Urba, W. J., Montesarchio, V., Weber, J. S., Wei, H., Wigginton, J. M., & Ascierto, P. A. (2020). The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response. Journal for Immunotherapy of Cancer, 8(1). https://doi.org/10.1136/jitc-2020-000930
Arnaldez FI, et al. The Society for Immunotherapy of Cancer Perspective On Regulation of Interleukin-6 Signaling in COVID-19-related Systemic Inflammatory Response. J Immunother Cancer. 2020;8(1) PubMed PMID: 32385146.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response. AU - Arnaldez,Fernanda I, AU - O'Day,Steven J, AU - Drake,Charles G, AU - Fox,Bernard A, AU - Fu,Bingqing, AU - Urba,Walter J, AU - Montesarchio,Vincenzo, AU - Weber,Jeffrey S, AU - Wei,Haiming, AU - Wigginton,Jon M, AU - Ascierto,Paolo Antonio, PY - 2020/04/15/accepted PY - 2020/5/10/entrez PY - 2020/5/10/pubmed PY - 2020/5/15/medline KW - immunomodulation KW - inflammation mediators JF - Journal for immunotherapy of cancer JO - J Immunother Cancer VL - 8 IS - 1 N2 - The pandemic caused by the novel coronavirus SARS-CoV-2 has placed an unprecedented burden on healthcare systems around the world. In patients who experience severe disease, acute respiratory distress is often accompanied by a pathological immune reaction, sometimes referred to as 'cytokine storm'. One hallmark feature of the profound inflammatory state seen in patients with COVID-19 who succumb to pneumonia and hypoxia is marked elevation of serum cytokines, especially interferon gamma, tumor necrosis factor alpha, interleukin 17 (IL-17), interleukin 8 (IL-8) and interleukin 6 (IL-6). Initial experience from the outbreaks in Italy, China and the USA has anecdotally demonstrated improved outcomes for critically ill patients with COVID-19 with the administration of cytokine-modulatory therapies, especially anti-IL-6 agents. Although ongoing trials are investigating anti-IL-6 therapies, access to these therapies is a concern, especially as the numbers of cases worldwide continue to climb. An immunology-informed approach may help identify alternative agents to modulate the pathological inflammation seen in patients with COVID-19. Drawing on extensive experience administering these and other immune-modulating therapies, the Society for Immunotherapy of Cancer offers this perspective on potential alternatives to anti-IL-6 that may also warrant consideration for management of the systemic inflammatory response and pulmonary compromise that can be seen in patients with severe COVID-19. SN - 2051-1426 UR - https://www.unboundmedicine.com/medline/citation/32385146/The_Society_for_Immunotherapy_of_Cancer_perspective_on_regulation_of_interleukin_6_signaling_in_COVID_19_related_systemic_inflammatory_response_ DB - PRIME DP - Unbound Medicine ER -